CCO Conference Highlights of the ESMO 2019 Congress

September 27 - October 1, 2019; Barcelona, Spain
Download this summary slideset of the key data in breast cancer, gastrointestinal cancers, gynecologic cancers, and thoracic malignancies from the 2019 Oncology meeting in Barcelona!
Axel Grothey Headshot
Axel Grothey, MD
Sara Hurvitz, MD, FACP
Bradley J. Monk, MD, FACS, FACOG
Sandip P. Patel, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.53 MB
Released: October 10, 2019

Acknowledgements

Supported by educational grants from
AbbVie
Agios Pharmaceuticals
Bristol-Myers Squibb
Eisai
PharmaMar

Related Content

Final OS data for PAOLA-1 phase III trial of maintenance olaparib plus bevacizumab vs placebo plus bevacizumab in newly diagnosed ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 27, 2022

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: September 26, 2022

DESTINY-Lung02 interim analyses: efficacy/safety of 2 doses of T-DXd (5.4 mg/kg and 6.4 mg/kg) in patients with HER2-mutated NSCLC and at least 1 previous therapy, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 26, 2022

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Released: September 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings